Will the FDA approve a new treatment for Long COVID based on the findings of the Iwasaki study by December 31, 2024?

Will Akiko Iwasaki or her colleagues publish a follow-up study on Long COVID by December 31, 2024?

Will the CDC introduce new Long COVID treatment guidelines based on the Iwasaki study by December 31, 2024?

What will follow-up studies identify as the primary location of persistent SARS-CoV-2 in Long COVID patients by December 31, 2024?

What will be the primary symptom targeted by new Long COVID treatments developed based on the Iwasaki study by December 31, 2024?

What will be the major funding source for new Long COVID research initiatives based on the Iwasaki study by December 31, 2024?